A 24-year-old man with type 1 diabetes mellitus is admitted to the intensive care unit for the management of diabetic ketoacidosis precipitated by viral gastroenteritis. He has been receiving aggressive intravenous fluid resuscitation, potassium supplementation, and a continuous regular insulin infusion. Eighteen hours after admission, he is alert, reports feeling hungry, and has no nausea. Current laboratory studies show a serum glucose of , a serum bicarbonate of , an anion gap of , and a venous pH of . The physician determines the patient is ready to transition to a subcutaneous insulin regimen. Arrange the following steps in the correct chronological sequence to safely de-escalate therapy and establish ongoing monitoring.
- 1Verify the resolution of ketoacidosis and confirm the patient's ability to tolerate oral intake.
- 2Administer the first scheduled dose of subcutaneous basal and prandial insulin.
- 3Maintain the continuous intravenous regular insulin infusion for an additional 1 to 2 hours.
- 4Discontinue the continuous intravenous regular insulin infusion.
- 5Transfer to a standard medical ward and initiate routine point-of-care blood glucose monitoring.
Answer
The correct sequence for transitioning a patient from an intravenous insulin infusion to subcutaneous insulin involves first verifying DKA resolution, followed by administering subcutaneous insulin, overlapping the intravenous infusion for 1 to 2 hours, discontinuing the intravenous infusion, and finally transferring the patient for routine ward monitoring.
The successful transition from intravenous to subcutaneous insulin requires careful sequencing to prevent relapse into diabetic ketoacidosis (DKA). First, objective resolution of DKA (closed anion gap, normalized pH) and clinical stability (ability to eat) must be confirmed. Next, subcutaneous basal and prandial insulin is administered. Because subcutaneous insulin has a delayed onset of action, the continuous intravenous insulin infusion must be maintained for a 1- to 2-hour overlap period. Discontinuing the infusion too early creates a dangerous window of absolute insulin deficiency, leading to rapid lipolysis, ketogenesis, and rebound DKA. Once the overlap period is complete, the intravenous infusion is stopped, and the patient is stepped down to a medical ward with routine glucose monitoring to evaluate the new regimen.
Step-by-Step Solution
Key Concept
To prevent rebound diabetic ketoacidosis during the transition to subcutaneous insulin, a 1- to 2-hour overlap with the intravenous insulin infusion is mandatory after the first subcutaneous injection.